Who offers digital therapeutics for smoking cessation that are clinically validated?

If by “clinically validated” you mean a digital smoking-cessation intervention supported by randomized clinical-trial evidence—not merely a wellness app—the field is relatively small.

Company / product	Evidence	Regulatory status / notes
Quit Genius	A randomized controlled trial of 556 adults found significantly higher 7-day abstinence at 4 weeks (44.5% vs. 28.7% with very brief advice). Follow-up analyses also reported higher abstinence at 26 and 52 weeks.PubMed Central (PMC)+2	Strong clinical evidence, but I would not characterize it as an FDA-authorized prescription digital therapeutic based on the sources I found.
Pivot / Pivot Breathe (Pivot Health Technologies)	Clinical studies have evaluated the program, which combines an app, FDA-cleared personal CO breath sensor, behavioral therapy and human coaching.JMIR mHealth and uHealth+1	The CO sensor is FDA-cleared; the overall smoking-cessation program is a digital health/behavior-change product rather than an FDA-authorized prescription DTx. Pivot currently markets Pivot Breathe as clinically validated.Pivot
Smokefree / CDC digital interventions	CDC identifies text messaging and web-based interventions as evidence-based aids that can help people quit.CDC	Public-health interventions rather than commercial prescription DTx.

An important distinction

There currently appears to be no FDA-authorized prescription digital therapeutic specifically for smoking cessation comparable to the FDA-authorized DTx products for conditions such as insomnia, depression, diabetes, or migraine. The FDA's digital-therapeutics landscape is broader, but smoking cessation has largely remained in the digital behavioral-health / mHealth category rather than FDA-authorized prescription software.Nature+1

Also, “clinically validated” can mean very different things. For diligence purposes, I'd separate:

1. Randomized controlled trial evidence for actual abstinence.
2. Biochemical verification of abstinence (e.g., CO).
3. Long-term outcomes at 6–12 months.
4. FDA clearance/authorization of the software itself.
5. Whether the intervention is prescription-only, employer-sponsored, or direct-to-consumer.
6. Whether it incorporates NRT/varenicline/bupropion or is software-only.

For example, Quit Genius has particularly relevant RCT evidence, while Pivot has a more comprehensive digital + sensor + coaching model.PubMed Central (PMC)+1

If you're asking because you're evaluating vendors for a health plan, employer, pharma company, or clinical program, I can also give you a 2026 landscape of ~10 smoking-cessation digital therapeutics/digital health vendors, with clinical-trial size, quit rates, FDA status, pricing/business model, and whether they offer white-label/API integration.

If by “clinically validated” you mean a smoking-cessation digital therapeutic with peer-reviewed clinical-trial evidence—not merely an app with educational content—the current field is relatively small.

Provider / product	Approach	Clinical evidence	Key point
2Morrow Health — 2MorrowQuit / SmartQuit / iCanQuit lineage	Acceptance & Commitment Therapy (ACT)	Strong — Phase III randomized trial, 2,415 adults, 12-month follow-up	The underlying ACT intervention was tested in a large RCT published in JAMA Internal Medicine. 2Morrow licenses the technology for commercial use.2Morrow+1
Quit Genius	Digital CBT, with clinician support	Strong — randomized trial, 556 adults	At 4 weeks post-quit date, 44.5% of the treatment group versus 28.7% of controls reported 7-day abstinence; longer-term secondary outcomes have also been published.PubMed+1
Pivot Health — Pivot	App + FDA-cleared carbon-monoxide breath sensor + coaching; commonly combined with NRT	Moderate/strong — randomized trial with biochemically validated outcomes	In a pilot RCT, biochemically validated abstinence was 29% vs 13% at 12 weeks and 21% vs 10% at 26 weeks compared with QuitGuide.PubMed+1

A couple of important distinctions

2Morrow has perhaps the clearest evidence base for a digital behavioral therapeutic specifically. The pivotal trial enrolled 2,415 smokers across all 50 U.S. states and followed them for 12 months. The intervention was the ACT-based iCanQuit app; 2Morrow subsequently licensed the underlying technology for commercial use.2Morrow+1

Quit Genius has a randomized controlled trial specifically describing it as a digital therapeutic intervention. Its intervention is clinician-assisted CBT and can incorporate nicotine-replacement therapy.PubMed+1

Pivot is somewhat different: it combines a smartphone program, human coaching, and a FDA-cleared carbon-monoxide breath sensor. Its RCT used biochemical validation of abstinence, which is a particularly useful feature when assessing cessation efficacy.PubMed+1

One caveat: “clinically validated” does not necessarily mean FDA-approved/cleared as a digital therapeutic. FDA-approved smoking-cessation treatments currently include medications such as nicotine replacement therapy, bupropion, and varenicline; FDA describes behavioral counseling in combination with these treatments as a first-line approach. U.S. Food and Drug Administration The clinical evidence for these digital programs is a separate question from regulatory authorization.

If you're evaluating these for a health plan, employer benefit, health system, or investment/market landscape, I can also give you a more comprehensive table covering FDA status, RCT sample size, abstinence rates, study quality, payer/employer availability, pricing, and whether each product is a true DTx versus a digital health app.

Yes. If by “digital therapeutics” you mean software-based interventions with published clinical evidence—not merely wellness/quit-smoking apps—the field is fairly small.

Strongest clinically validated options

• Quit Genius — Probably the clearest example of a smoking-cessation digital therapeutic. It delivers digital cognitive behavioral therapy (CBT), with clinician support and, in studies, nicotine-replacement therapy (NRT). A randomized controlled trial of 556 smokers found 4-week abstinence of 44.5% vs. 28.7% with brief advice (RR 1.55, P<.001). Longer-term analyses have also examined outcomes at 26 and 52 weeks.PubMed+1
• Pivot — A digital smoking-cessation program from Pivot Health that combines a smartphone program, behavioral support, NRT, and a connected carbon-monoxide breath sensor. In a randomized pilot trial, biochemically confirmed abstinence at 12 weeks was 29% vs. 13% for the comparison app, and continuous abstinence at 26 weeks was 21% vs. 10%. A subsequent analysis found benefits persisting to 52 weeks.PubMed+1
• quitSTART / Smokefree — A free government-developed cessation app from the National Cancer Institute's Smokefree program, developed with FDA input. It is evidence-informed and clinically oriented, but I would classify it as a digital cessation intervention rather than a prescription digital therapeutic (DTx).Smokefree+1

An important distinction

There is a difference between “clinically validated” and “FDA-authorized as a digital therapeutic.” The FDA has a device classification specifically covering software-based computerized behavioral therapy for substance-use disorders, but that does not mean every smoking-cessation app with an RCT has FDA clearance.FDA Access Data

In fact, I would not currently describe the U.S. market as having a broad selection of FDA-cleared prescription smoking-cessation DTx products. The strongest evidence is currently around programs such as Quit Genius and Pivot, while many other apps have considerably weaker clinical evidence. WHO likewise gives digital tobacco-cessation interventions a conditional recommendation, with moderate certainty for text messaging but lower certainty for smartphone apps and AI interventions.NCBI

If you're evaluating vendors

I'd put them into roughly three tiers:

One caveat: FDA approval of the underlying treatment matters too. FDA-approved medications such as varenicline, bupropion and NRT remain first-line cessation treatments, and digital interventions are often most effective when combined with pharmacotherapy and/or counseling.U.S. Food and Drug Administration+1

If you're asking because you're evaluating companies for investment, partnership, health-plan coverage, or a clinical program, I can also give you a more comprehensive competitive landscape of 10–20 smoking-cessation DTx companies, including clinical-trial evidence, FDA status, business model, customers, and whether they sell B2B/B2C.

Yes. If by “clinically validated digital therapeutics” you mean software-based smoking-cessation interventions supported by randomized clinical evidence—not merely wellness apps—the field is relatively small.

Strongest examples

Company / product	Evidence	Regulatory status	Comments
Click Therapeutics — Clickotine®	Clinical evidence supporting a structured digital smoking-cessation intervention	Not FDA-cleared specifically for smoking cessation	CBT/behavioral program delivered via smartphone; historically integrated with nicotine-replacement therapy (NRT). Click describes it as a clinically validated smoking-cessation program.Click Therapeutics+1
Digital Therapeutics, Inc. / Quit Genius	Randomized controlled trial, n=556; 44.5% vs. 28.7% 7-day abstinence at 4 weeks, RR 1.55, P<.001	Not FDA-cleared as a smoking-cessation DTx	One of the better-published examples. It uses clinician-assisted CBT and incorporates medication/NRT support. Longer-term outcomes have also been published.PubMed+1
DynamiCare Health	Clinical evidence for digital contingency-management approaches, including smoking cessation	Received FDA Breakthrough Device designation for a smoking-cessation application in a particular population; breakthrough designation ≠ clearance/approval	Particularly interesting if you're looking for contingency management/reward-based digital treatment rather than conventional CBT. A review rates the evidence as moderate.PubMed Central (PMC)

An important distinction

There currently appears to be a gap between “clinically validated” and “FDA-authorized prescription digital therapeutic for smoking cessation.” I would not describe any of the above as an FDA-cleared smoking-cessation prescription DTx based on the evidence I found.

For comparison, FDA-cleared prescription DTx products such as Pear's reSET are authorized for substance use disorder, not specifically tobacco/nicotine cessation.Pear Therapeutics+1

There is also substantial clinical evidence for smartphone-based cessation interventions generally. For example, the Quit Genius RCT found significantly higher short-term abstinence than very brief advice, while other randomized trials have demonstrated efficacy for specific behavioral approaches delivered through smartphone apps.PubMed+1

If you're evaluating vendors

I'd separate the market into three tiers:

1. Clinically validated DTx: Quit Genius, Clickotine, DynamiCare.
2. Evidence-based digital cessation programs: numerous apps/programs with RCT or observational evidence, but not necessarily regulated as DTx.
3. FDA-authorized prescription DTx: very few overall, and none that I could substantiate as FDA-authorized specifically for smoking cessation.

If you're asking this from a health-plan, employer, pharma, or investment perspective, I can also build you a more useful 2026 competitive landscape with ~10–15 companies, including clinical-trial size/results, FDA status, NRT integration, payer/employer distribution, pricing/business model, and whether the product is actually available today.

An important distinction

There currently appears to be a gap between “clinically validated” and “FDA-authorized prescription digital therapeutic for smoking cessation.” I would not describe any of the above as an FDA-cleared smoking-cessation prescription DTx based on the evidence I found.

For comparison, FDA-cleared prescription DTx products such as Pear's reSET are authorized for substance use disorder, not specifically tobacco/nicotine cessation.pearstherapeutics.com+1

There is also substantial clinical evidence for smartphone-based cessation interventions generally. For example, the Quit Genius RCT found significantly higher short-term abstinence than very brief advice, while other randomized trials have demonstrated efficacy for specific behavioral approaches delivered through smartphone apps.

If you're evaluating vendors

I'd separate the market into three tiers:

Digital therapeutics (DTx) and evidence-based digital health platforms for smoking cessation combine behavioral mechanics—such as Cognitive Behavioral Therapy (CBT) and Motivational Enhancement Therapy (MET)—with tracking technology, biosensors, and human coaching.pubmed.ncbi.nlm.nih.gov+2

Several key providers offer clinically validated or evidence-backed digital solutions in this space:

• Pivot (by Centerfirst / formerly Carrot Wellness)
  • The Solution: Pivot features a comprehensive mobile app paired with an FDA-cleared, OTC-labeled carbon monoxide (CO) breath sensor that connects via Bluetooth to help users visualize their reduction progress. It also includes dedicated one-on-one human coaching and peer support communities.
  • Clinical Validation: Built around US Clinical Practice Guidelines for tobacco cessation, published clinical studies on Pivot have demonstrated significant engagement, reduction in cigarette consumption, and verified quit rates. It is primarily deployed via employers and health plans . Learn more on the Pivot Smoking Cessation Platform.pivot.co+1
• Clickotine (by Click Therapeutics)
  • The Solution: A fully digital, personalized behavioral modification program designed to reduce cravings and anxiety associated with nicotine withdrawal. It often integrates with health plans (such as Magellan Health) alongside coaching and nicotine replacement therapies (NRT).
  • Clinical Validation: Supported by open-label clinical trials and prospective studies evaluating its efficacy in helping individuals achieve multi-week smoke-free milestones. Details are accessible via Click Therapeutics.clicktherapeutics.com+3
• iCanQuit (developed by researchers / academic trials)
  • The Solution: An evidence-based smartphone app utilizing Acceptance and Commitment Therapy (ACT) rather than traditional strict behavioral modification alone.
  • Clinical Validation: Evaluated in large-scale randomized controlled trials (RCTs) published in peer-reviewed medical journals, showing significantly higher 12-month quit rates compared to standard public quit guides—especially when combined with FDA-approved cessation medications.pmc.ncbi.nlm.nih.gov+1
• Alex Therapeutics (Elia platform)
  • The Solution: Collaborates with major pharmaceutical companies (such as Pfizer in Europe) to build evidence-backed, highly customized CBT-driven digital cessation apps.
  • Clinical Validation: Employs rigorous psychological frameworks combined with structured clinical evaluation studies prior to regional rollouts. Further information can be found at Alex Therapeutics.fiercebiotech.com+1

If you're looking for a program to use, would you prefer a solution accessed through an employer/health plan benefit (like Pivot) or an independent app ? I can also share details on how these apps pair with nicotine replacement therapies (NRT).